EpCAM Antibody / Extracellular domain

EpCAM (Epithelial Cell Adhesion Molecule), also known as CD326, plays a crucial role in various cellular processes and has been linked to the development and progression of cancer. EpCAM is a transmembrane glycoprotein that is expressed in high levels on the surface of epithelial cells. In cancer cells, the expression of EpCAM is often upregulated, leading to increased cell proliferation, invasion, and metastasis. Studies have shown that high levels of EpCAM are associated with poor prognosis in various types of cancer, including breast, colon, and lung cancer. The overexpression of EpCAM in cancer cells makes it an attractive target for diagnostic and therapeutic purposes. Researchers are exploring the use of EpCAM as a biomarker for early cancer detection through blood tests and imaging techniques. In addition, EpCAM-targeted therapies, such as monoclonal antibodies and immunotherapies, are being developed to specifically target and kill cancer cells that overexpress EpCAM.